Daridorexant and Fentanyl Transdermal Patch: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Daridorexant
No brand names on recordFentanyl Transdermal Patch
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased CYP3A4 substrate with NTI exposure and an increased risk CNS depression
Interaction Deep Dive
Concomitant use of daridorexant with other CNS depressants which are also CYP3A4 substrate with NTI, may increase the exposure to CYP3A4 substrate with NTI and may lead to additive impairment of psychomotor performance, including daytime impairment, and risk of CNS depression. Use with caution in patients receiving CNS depressants which are also CYP3A4 substrate with NTI and consider dose adjustment of daridorexant and/or the CNS depressant if used concomitantly1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism by daridorexant; additive impairment of psychomotor performance and CNS depression
Literature reports
1 report — tap to read
a) Concomitant use of single dose daridorexant 50 mg and midazolam (CYP3A4 substrate) 2 mg increased daridorexant AUC by a geometric mean ratio (GMR) of 1.4 (90% CI, 1.3 to 1.6) and Cmax by a GMR of 1.1 (90% CI, 1 to 1.3) 1.
Common questions
Can I take Daridorexant and Fentanyl Transdermal Patch together?
Increased CYP3A4 substrate with NTI exposure and an increased risk CNS depression Always confirm with your pharmacist or prescriber before making any change.
How serious is the Daridorexant and Fentanyl Transdermal Patch interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Daridorexant or Fentanyl Transdermal Patch need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: QUVIVIQ(R) oral tablets, daridorexant oral tablets. Idorsia Pharmaceuticals US Inc (per FDA), Radnor, PA, 2023. DailyMed
Keep reading about Daridorexant
Keep reading about Fentanyl Transdermal Patch
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist